Multivariate analysis for specific toxicities (grades 3-5) and NRM
. | Infection . | . | Hepatic . | . | 1-year NRM . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Risk factor . | OR (95% CI) . | P . | OR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Type of regimen | |||||||||
| Nonablative vs ablative | 0.2 (0.1-0.4) | < 10-4 | 0.3 (0.1-0.6) | .002 | 0.4 (0.2-1.0) | .06 | |||
| Comorbidity score | NS | NS | .002 | ||||||
| 0 | Reference | ||||||||
| 1,2 | 3.3 (1.6-7.1) | ||||||||
| 3 or more | 7.9 (2.0-31) | ||||||||
| CMV risk* | |||||||||
| High vs low/intermediate | 3.4 (1.4-8.1) | .004 | NS | NS | |||||
| Diagnosis group | .04 | NS | NS | ||||||
| AML, MDS | Reference | ||||||||
| MM | 0.3 (0.1-0.9) | ||||||||
| NHL, HD, Waldenstrom | 0.5 (0.2-1.6) | ||||||||
| CLL, CML, ALL | 1.5 (0.4-5.5) | ||||||||
| Hematopoietic cell source | |||||||||
| Marrow vs G-PBMC | NS | 3.1 (1.1-8.8) | .03 | 2.9 (1.3-6.9) | .02 | ||||
. | Infection . | . | Hepatic . | . | 1-year NRM . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Risk factor . | OR (95% CI) . | P . | OR (95% CI) . | P . | HR (95% CI) . | P . | |||
| Type of regimen | |||||||||
| Nonablative vs ablative | 0.2 (0.1-0.4) | < 10-4 | 0.3 (0.1-0.6) | .002 | 0.4 (0.2-1.0) | .06 | |||
| Comorbidity score | NS | NS | .002 | ||||||
| 0 | Reference | ||||||||
| 1,2 | 3.3 (1.6-7.1) | ||||||||
| 3 or more | 7.9 (2.0-31) | ||||||||
| CMV risk* | |||||||||
| High vs low/intermediate | 3.4 (1.4-8.1) | .004 | NS | NS | |||||
| Diagnosis group | .04 | NS | NS | ||||||
| AML, MDS | Reference | ||||||||
| MM | 0.3 (0.1-0.9) | ||||||||
| NHL, HD, Waldenstrom | 0.5 (0.2-1.6) | ||||||||
| CLL, CML, ALL | 1.5 (0.4-5.5) | ||||||||
| Hematopoietic cell source | |||||||||
| Marrow vs G-PBMC | NS | 3.1 (1.1-8.8) | .03 | 2.9 (1.3-6.9) | .02 | ||||
Other factors considered, but not found to be significant, were age, previous HCT, time from diagnosis to transplantation, disease risk, and donor sex. NRM indicates nonrelapse mortality; OR, odds ratio; HR, hazard ratio; CI, confidence interval; NS, not significant; CMV, cytomegalovirus; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphocytic leukemia; G-PBMC, granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells.
High-risk CMV indicates patient CMV+